Shots:
- HilleVax gets an exclusive license for the development and commercialization rights of Takeda’s HIL-214 globally (Ex-Japan). Takeda will hold the commercialization rights of the vaccine in Japan
- Takeda will focus primarily on dengue, COVID-19, pandemic influenza and Zika vaccines. HilleVax will merge Japan development activities into its global development
- HIL-214 is a VLP based vaccine that has completed a P-IIb efficacy study in 4,712 adults, demonstrated clinical POC in preventing mod. to sev. acute gastroenteritis from norovirus infection. The vaccine was well-tolerated
Click here to to read full press release/ article | Ref: GlobeNewswire | Image: GeneOnline
The post Takeda and Frazier Collaborate to Launch HilleVax (biopharma company) for the Development of Norovirus Vaccine first appeared on PharmaShots.
